Valeant Pharmaceuticals gets cease-trading order

1 April 2016

A cease-trade order has been issued to the directors and key officers of Canada-based Valeant Pharmaceuticals International (TSX: VRX) after the company failed to file its annual financial statements on time, it has emerged.

Valeant said it requested the temporary order pending its filing of audited financial statements for 2015.

A spokesperson said: “As previously announced, Valeant asked the Autorité Des Marches Financiers (AMF), the company’s principal regulator in Canada, for a management cease-trade order pending filing of the audited annual financial statements for the year ended December 2015, the related management’s discussion and analysis, certificates of its CEO and CFO and its 2015 Form 10-K.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK